Ozempic and Mounjaro’s smashing success is just the beginning for biopharma’s obesity-drug arms race
Eli Lilly and Novo Nordisk have revolutionized the weight loss and diabetes drug space. Now, a flood of other GLP-1 drugs are on the horizon.
Read the article on Fast Company >
Read More from the Global Wellness News ™